Cirrhotic patients on proton pump inhibitors are at a twofold risk of spontaneous bacterial peritonitis independently of gastrointestinal bleeding: a population-based retrospective study

Background Recent findings suggest that cirrhotic patients on proton pump inhibitors (PPIs) are at a higher risk for developing spontaneous bacterial peritonitis (SBP) than non-PPI users. We aimed to identify whether PPI use is an independent risk factor for the development of SBP among cirrhotic patients in the United States (US). Methods We enrolled a retrospective cohort using a validated multicenter database. Patients with a SNOMED-CT diagnosis of “cirrhosis” between 1999 and 2022 were identified. All patients below 18 years of age were excluded. We calculated the prevalence of individuals using PPIs in the total US population and in cirrhotic patients from 1999 to date, and the incidence of SBP in the past year. Finally, we constructed a multivariate regression model, controlling for multiple covariates. Results The final analysis included 377,420 patients. The 20-year-period prevalence of SBP in patients with cirrhosis was 3.54% and the prevalence of patients using PPIs in the US population was 12,000 per 100,000 people (12.00%). The 1-year incidence of SBP in cirrhotic patients using PPIs was 2500 per 100,000 people. After accounting for confounders, the risk of SBP was higher among males, patients with a diagnosis of gastrointestinal bleeding, and those using β-blockers and PPIs. Conclusions To date, this is the largest cohort used to examine the prevalence of SBP among cirrhotic patients in the US. PPI use and hepatic encephalopathy offered the highest risk for the development of SBP, independently of gastrointestinal bleeding. Focusing on judicious PPI use should be encouraged among cirrhotic patients.

[1]  Imad Asaad,et al.  Epidemiology and prevalence of lean nonalcoholic fatty liver disease and associated cirrhosis, hepatocellular carcinoma, and cardiovascular outcomes in the United States: a population‐based study and review of literature , 2022, Journal of gastroenterology and hepatology.

[2]  Prabhat Kumar,et al.  Prevalence of hypothyroidism and effect of thyroid hormone replacement therapy in patients with non-alcoholic fatty liver disease: A population-based study , 2022, World journal of hepatology.

[3]  G. S. Kew,et al.  An Epidemiological Meta-Analysis on the Worldwide Prevalence, Resistance, and Outcomes of Spontaneous Bacterial Peritonitis in Cirrhosis , 2021, Frontiers in Medicine.

[4]  M. Boustani,et al.  Increasing Economic Burden in Hospitalized Patients With Cirrhosis: Analysis of a National Database , 2019, Clinical and translational gastroenterology.

[5]  P. Andersen,et al.  Effect of proton pump inhibitors on the risk and prognosis of infections in patients with cirrhosis and ascites , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[6]  S. Marciano,et al.  Spontaneous bacterial peritonitis in patients with cirrhosis: incidence, outcomes, and treatment strategies , 2019, Hepatic medicine : evidence and research.

[7]  M. Manns,et al.  Dose‐dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[8]  A. Waness,et al.  Increased Risk of Spontaneous Bacterial Peritonitis in Cirrhotic Patients Using Proton Pump Inhibitors , 2018, GE - Portuguese Journal of Gastroenterology.

[9]  T. Shizuma Spontaneous bacterial and fungal peritonitis in patients with liver cirrhosis: A literature review , 2018, World journal of hepatology.

[10]  T. Woreta,et al.  Mortality from Spontaneous Bacterial Peritonitis Among Hospitalized Patients in the USA , 2018, Digestive Diseases and Sciences.

[11]  C. Tovo,et al.  Influence of proton pump inhibitors in the development of spontaneous bacterial peritonitis , 2017, World journal of hepatology.

[12]  D. Rockey,et al.  Trends in Hospitalization, Acute Kidney Injury, and Mortality in Patients With Spontaneous Bacterial Peritonitis , 2017, Journal of clinical gastroenterology.

[13]  K. Koh,et al.  Proton pump inhibitors do not increase the risk for recurrent spontaneous bacterial peritonitis in patients with cirrhosis , 2017, Journal of gastroenterology and hepatology.

[14]  A. Martins,et al.  Clinical and microbiological characteristics associated with mortality in spontaneous bacterial peritonitis: a multicenter cohort study , 2016, European journal of gastroenterology & hepatology.

[15]  F. Bendtsen,et al.  Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[16]  G. Garcia‐Tsao Current Management of the Complications of Cirrhosis and Portal Hypertension: Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis , 2016, Digestive Diseases.

[17]  A. Krag,et al.  Nonselective β‐blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients , 2015, Hepatology.

[18]  H B Xu,et al.  Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. , 2015, Genetics and molecular research : GMR.

[19]  Y. Tsai,et al.  Risk of Spontaneous Bacterial Peritonitis Associated With Gastric Acid Suppression , 2015, Medicine.

[20]  F. Barreyro,et al.  Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study. , 2015, Journal of hepatology.

[21]  K. Reddy,et al.  Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  J. González-Navajas,et al.  Use of proton pump inhibitors decrease cellular oxidative burst in patients with decompensated cirrhosis , 2015, Journal of gastroenterology and hepatology.

[23]  S. Bota,et al.  Proton Pump Inhibitor Intake neither Predisposes to Spontaneous Bacterial Peritonitis or Other Infections nor Increases Mortality in Patients with Cirrhosis and Ascites , 2014, PloS one.

[24]  Adrian V. Hernández,et al.  Acid‐suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: A meta‐analysis , 2013, Journal of gastroenterology and hepatology.

[25]  P. Siersema,et al.  Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability , 2012, European journal of clinical investigation.

[26]  Anil K. Jain,et al.  Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[27]  Stuart J. Nelson,et al.  Normalized names for clinical drugs: RxNorm at 6 years , 2011, J. Am. Medical Informatics Assoc..

[28]  G. Trikudanathan,et al.  Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients – a systematic review and meta‐analysis , 2011, International journal of clinical practice.

[29]  A. Burroughs,et al.  Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. , 2010, Gastroenterology.

[30]  S. Møller EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. , 2010, Journal of hepatology.

[31]  R. Hoffmann,et al.  Association of Proton Pump Inhibitor Therapy With Spontaneous Bacterial Peritonitis in Cirrhotic Patients With Ascites , 2009, The American Journal of Gastroenterology.

[32]  K. Obstein,et al.  Association between Proton Pump Inhibitor Use and Spontaneous Bacterial Peritonitis , 2008, Digestive Diseases and Sciences.

[33]  M. Navasa,et al.  Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. , 2007, Gastroenterology.

[34]  A. Sanyal,et al.  Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis , 2007, The American Journal of Gastroenterology.

[35]  J. Hoefs,et al.  Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club , 2005, Gut.

[36]  Miriam C J M Sturkenboom,et al.  Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. , 2004, JAMA.

[37]  M. Navasa,et al.  Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis , 2002, Hepatology.

[38]  B. West,et al.  Omeprazole Inhibits Phagocytosis and Acidification of Phagolysosomes of Normal Human Neutrophils In Vitro , 2000, Immunopharmacology and immunotoxicology.

[39]  R. Fisher,et al.  Effect of gastric acid suppressants on human gastric motility , 1998, Gut.

[40]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[41]  S. Schulz,et al.  Systematized Nomenclature of Medicine Clinical Terms ( SNOMED CT ) , 2021 .

[42]  T. Gustot,et al.  Management of bacterial infections in cirrhosis. , 2012, Journal of hepatology.

[43]  A. Chotchaeva,et al.  [Effect of HP eradication on the development of gastroesophageal reflux disease: results of the prospective study]. , 2011, Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology.

[44]  G. D’Amico,et al.  Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. , 2006, Journal of hepatology.

[45]  J. Such,et al.  Spontaneous Bacterial Peritonitis , 1997, Seminars in liver disease.